Publications by authors named "S Takaki"
Article Synopsis
- - Medication adherence is crucial for effective treatment in chronic diseases, particularly cardiovascular diseases (CVDs), and this study aimed to assess adherence using both subjective (self-reported surveys) and objective (pill counting) methods among outpatients from Fukuoka University Chikushi Hospital.
- - The study involved 94 patients and found no significant differences in adherence when comparing subjective survey scores with objective pill counting results, highlighting a discrepancy between how patients perceive their adherence and actual medication-taking behavior.
- - A multivariate analysis identified obesity as a significant factor linked to poor medication adherence, suggesting that healthcare providers should pay extra attention to patients with CVD who are also obese.
Background: Polymyxin-B direct hemoperfusion (PMX-DHP) is an endotoxin adsorption column-based blood purification therapy. Since one of the most potent effects of PMX-DHP is blood pressure elevations, it may be the most effective when it is introduced at the time when the need for vasopressors is the greatest, which, in turn, may reduce mortality.
Methods: A multicenter retrospective study was conducted at 24 ICUs in Japan.
Article Synopsis
- The study aimed to identify characteristics of patients with non-refractory Kawasaki disease (KD) who responded well to standard IVIG treatment and explore factors linked to coronary artery (CA) complications.
- A total of 69,735 non-refractory KD patients were studied, with 0.96% developing CA abnormalities, particularly influenced by initial echocardiographic findings and factors like age and gender.
- The research concluded that about 1% of non-refractory KD patients might face CA complications and emphasized the need for timely echocardiographic assessments and early IVIG treatment initiation.
Article Synopsis
- - This study explores the effectiveness of combining immune checkpoint inhibitors durvalumab and tremelimumab (DT) for patients with hepatocellular carcinoma (HCC) who previously received treatments like atezolizumab plus bevacizumab (AB).
- - Results showed objective response rates (ORRs) were highest in first-line treatment (44%), followed by second-line without prior AB (54%), and significantly lower in patients who had prior AB (5%), indicating that prior treatment heavily affects success.
- - The findings suggest that while DT may be less effective after AB treatment, it can still yield similar results to first-line therapy in patients without prior AB, highlighting the importance of treatment history when planning HCC therapy.
Background/aim: Maintaining liver function throughout the treatment of hepatocellular carcinoma (HCC) is crucial, yet the impact of durvalumab plus tremelimumab (DT) treatment on liver function is not well understood. This multicenter study aimed to examine the changes in liver function during DT treatment.
Patients And Methods: This nationwide multicenter study included 80 patients who received DT treatment for unresectable HCC.